Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

Rhea-AI Summary

Bright Minds Biosciences (NASDAQ: DRUG), a company developing selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and CNS disorders, has announced its participation in three major healthcare conferences in March 2025.

The company's CEO Ian McDonald and senior management will attend:

• TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 1:10pm ET
• Leerink Partners Global Healthcare Conference in Miami on March 12, 2025 (one-on-one meetings)
• BIO-Europe Spring in Milan from March 17-19, 2025

Live and archived webcasts will be available on the company's investor relations website for 90 days following the events.

News Market Reaction

-0.14%

1 alert

-0.14% News Effect

On the day this news was published, DRUG declined 0.14%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and select members of senior management, will participate in three healthcare conferences, as follows:

TD Cowen 45th Annual Health Care Conference, Boston
Monday, March 3, 2025, at 1:10pm ET
Join the webcast

Leerink Partners Global Healthcare Conference, Miami
Wednesday, March 12, 2025 (1x1 meetings)

BIO-Europe Spring, Milan
March 17-19, 2025

The live and archived webcasts will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 90 days.

About Bright Minds Biosciences

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Website: www.brightmindsbio.com

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

What healthcare conferences will Bright Minds Biosciences (DRUG) attend in March 2025?

Bright Minds will participate in three conferences: TD Cowen Annual Health Care Conference in Boston (March 3), Leerink Partners Global Healthcare Conference in Miami (March 12), and BIO-Europe Spring in Milan (March 17-19).

When is Bright Minds Biosciences (DRUG) presenting at the TD Cowen conference?

Bright Minds will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 1:10pm ET in Boston.

How long will the webcasts be available for Bright Minds' (DRUG) March 2025 conference presentations?

The webcasts will be available for replay on the company's website for 90 days following the events.

What therapeutic areas is Bright Minds Biosciences (DRUG) focusing on?

Bright Minds is developing selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders.